Implications of the new biology for therapy in breast cancer.

Abstract:

:It is a truism that a better understanding of the biology of breast cancer should lead to improvements in diagnosis and therapy. Despite this, our significantly improved grasp of breast cancer biology has had little direct therapeutic impact to date. The technologies used to treat breast cancer (surgery, radiation therapy, chemotherapy, and hormonal therapy) were in general developed decades ago. With the exception of the prognostic factor area, advances in biological knowledge have not translated into either new therapies or altered outcomes. Fortunately, this now appears to be changing. This paper will focus on three emerging areas in which the new biology is most likely to have a therapeutic impact. The first area involves growth factors and their receptors. It is now clear that the growth of breast cancer is regulated by growth factor receptors (eg, EGFR and Her-2/neu), and that their upregulation is associated with impaired prognosis. Growth factors and their receptors represent a promising therapeutic target, both alone and in combination with other standard agents. Recent evidence suggests that growth factors and their receptors may be important for regulating programmed cell death (apoptosis) in breast cancer. A second emerging area involves matrix metalloproteinases. Breast cancer invasion and metastasis involves and requires activation of enzymes capable of dissolving natural barriers to spread. The most heavily studied of these are the matrix metalloproteinases, for which considerable in vitro and in vivo evidence suggests an important role in breast cancer. The recent advent of compounds with matrix metalloproteinase inhibitory activity makes a therapeutic intervention against matrix metalloproteinases appear reasonable. In vivo laboratory evidence suggests that their use may occur in the very near future. A third emerging area revolves around the question of neoangiogenesis (new blood vessel formation) in breast cancer. Breast cancers (indeed, all solid tumors) are incapable of growth beyond a certain critical diameter without new blood vessel formation. Recent work has demonstrated that breast cancers produce angiogenic factors stimulating this new growth. Therapies aimed at blocking this stimulation, and preventing neovascularization represent a promising therapeutic target. Numerous agents capable of preventing new blood vessel formation have been discovered in the laboratory and are poised to enter clinical trials.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Sledge GW Jr

subject

Has Abstract

pub_date

1996-02-01 00:00:00

pages

76-81

issue

1 Suppl 2

eissn

0093-7754

issn

1532-8708

journal_volume

23

pub_type

杂志文章,评审
  • Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy.

    abstract::Hypoxic areas are a characteristic property of solid tumors. Hypoxia results from an imbalance between the supply and consumption of oxygen. Major pathogenetic mechanisms for the emergence of hypoxia are (1) structural and functional abnormalities in the tumor microvasculature; (2) an increase in diffusion distances; ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90210-6

    authors: Vaupel P,Kelleher DK,Höckel M

    更新日期:2001-04-01 00:00:00

  • Surgical therapy of lung metastases.

    abstract::Almost 125 years after the first documented case, pulmonary metastasectomy is still poorly understood. No other organ is subject to the wide histologic variety of metastatic insults, and this fact has complicated a complete exposition of when pulmonary metastasectomy may be beneficial. Many physicians still consider p...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2007.03.004

    authors: Sternberg DI,Sonett JR

    更新日期:2007-06-01 00:00:00

  • Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.

    abstract::Modulation of the signaling pathways that are aberrant in cancer cells has the potential to provide an effective nontoxic approach to patient management in a broad range of cancers. This quest has taken a major leap forward with the demonstration that STI-571 (imatinib mesylate) induces clinical and molecular remissio...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2003.08.011

    authors: Mills GB,Kohn E,Lu Y,Eder A,Fang X,Wang H,Bast RC,Gray J,Jaffe R,Hortobagyi G

    更新日期:2003-10-01 00:00:00

  • Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.

    abstract::Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 1-hour infusion potentially offers its recipients reduced toxicity, demonstrated efficacy, and greater ease of administration. To confirm this hypothesis, we undertook a phase I/II study of 1-hour, single-agent paclitaxel in 164 patients' refra...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Hainsworth JD,Greco FA

    更新日期:1995-12-01 00:00:00

  • Reirradiation of recurrent head and neck cancers with curative intent.

    abstract::In patients with recurrent, previously irradiated head and neck cancer, the traditional therapy of palliative single- or multi-agent chemotherapy yields a 30% to 40% response rate with median survival durations of 8 to 10 months. However, long-term survival is rarely observed. Reirradiation with or without concurrent ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.09.003

    authors: Chmura SJ,Milano MT,Haraf DJ

    更新日期:2004-12-01 00:00:00

  • Anti-CTLA-4 antibody adjuvant therapy in melanoma.

    abstract::Thus far the development of adjuvant therapies in melanoma has suffered greatly from the lack of effective drugs in stage IV melanoma. Chemotherapy, cytokines, vaccines, and combinations of drugs have been used with minimal success. This has led to adjuvant therapies that are not used uniformly or widely because of th...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2010.09.009

    authors: Eggermont AM,Testori A,Maio M,Robert C

    更新日期:2010-10-01 00:00:00

  • Third-line salvage chemotherapy in Hodgkin's disease.

    abstract::CEP (CCNU, etoposide, and prednimustine) was tested as third-line chemotherapy in 40 patients resistant to both MOPP and ABVD. The observed response rate (complete remission, 35%, and partial remission, 25%) is encouraging. Treatment was generally well tolerated and all acute side effects were reversible. ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Bonadonna G,Viviani S,Valagussa P,Bonfante V,Santoro A

    更新日期:1985-03-01 00:00:00

  • Clinicopathologic factors influencing the long-term prognosis following hepatic resection for large hepatocellular carcinoma more than 10 cm in diameter.

    abstract::We resected 158 cases of hepatocellular carcinoma (HCC), including 20 (12.6%) cases of large HCC. These 20 cases were divided into group 1 (curative resection, n = 9) and group 2 (noncurative resection, n = 11). The clinicopathologic features and long-term survival of the cases were evaluated. In groups 1 and 2, porta...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Noguchi T,Kawarada Y,Kitagawa M,Ito F,Sakurai H,Machishi H,Yamagiwa K,Yokoi H,Mizumoto R

    更新日期:1997-04-01 00:00:00

  • Familial cancer and cancer families.

    abstract::From this brief review is should be evident that the hereditary varieties of common cancers are characterized by a high degree of genetic heterogeneity. The specific types of hereditary cancers can be identified by focusing on the histologic types and sites of involvement, not only of the primary neoplasm, but also of...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Anderson DE

    更新日期:1978-03-01 00:00:00

  • Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.

    abstract::Rituximab (Rituxan; IDEC Pharmaceuticals, San Diego, CA, and Genentech, Inc, San Francisco, CA) is a genetically engineered monoclonal antibody for the treatment of non-Hodgkin's lymphoma. This chimeric mouse/human, immunoglobulin GI kappa anti-CD20 antibody mediates complement-dependent cell lysis and antibody-depend...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Grillo-López AJ,White CA,Varns C,Shen D,Wei A,McClure A,Dallaire BK

    更新日期:1999-10-01 00:00:00

  • Surgery for support and palliation in patients with malignant disease.

    abstract::Surgery is the major curative treatment modality for patients with malignant disease. However, surgery also plays an important role in supportive and palliative care of cancer patients. In settings in which maintaining quality of life rather than prolongation of survival is the major goal of treatment, the potential m...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Markman M

    更新日期:1995-04-01 00:00:00

  • Use of preclinical models to assess the therapeutic potential of new drug candidates for bladder cancer.

    abstract::The purpose of this review is to demonstrate a successful use of preclinical models of bladder cancer to confirm the therapeutic potential of new promising drug candidates. The bladder has long been thought to be an ideal target for investigating therapies. When developing a new antineoplastic pharmaceutical agent, th...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2012.08.006

    authors: Amit D,Gofrit ON,Matouk I,Birman T,Hochberg A

    更新日期:2012-10-01 00:00:00

  • Challenges and opportunities for Erlotinib (Tarceva): what does the future hold?

    abstract::The development of targeted agents has brought new opportunities and extraordinary therapeutic challenges to cancer therapy. Several agents that inhibit epidermal growth factor receptor (HER1/EGFR) tyrosine kinase have been developed and are advanced in their clinical development. Preclinical and clinical data show th...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Hortobagyi GN,Sauter G

    更新日期:2003-06-01 00:00:00

  • Rituximab plus chemotherapy in follicular and mantle cell lymphomas.

    abstract::Rituximab shows high single-agent activity in both previously untreated and relapsed or refractory indolent non-Hodgkin's lymphoma. In combination with chemotherapy, rituximab has achieved response rates higher than 90% with long duration of remission in phase II studies. Therefore, randomized phase III studies have b...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验,评审

    doi:10.1053/sonc.2003.50024

    authors: Hiddemann W,Dreyling M,Unterhalt M

    更新日期:2003-02-01 00:00:00

  • The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma.

    abstract::Many patients with Hodgkin's and non-Hodgkin's lymphoma (NHL) can be cured today with combination chemotherapy and/or radiotherapy. However, for patients with suboptimal responses to initial therapy or for patients with refractory or relapsed disease, salvage therapy alone is usually inadequate to achieve long-term su...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Laport GF,Williams SF

    更新日期:1998-08-01 00:00:00

  • Mind the gap: An analysis of foregone health gains from unfunded cancer medicines in New Zealand.

    abstract::Publicly funded cancer medicines listed on the New Zealand Pharmaceutical Schedule were compared with those listed on the Australian Pharmaceutical Benefits Scheme. To quantify the health gains offered by the cancer medicines funded in Australia but not in New Zealand, clinical trial data reporting median progression-...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.10.004

    authors: Evans J,Laking G,Strother M,Wang T,Metcalfe S,Blick G,Pauls R,Crausaz S

    更新日期:2016-12-01 00:00:00

  • Surgical adjuvant chemotherapy in non-small cell lung cancer.

    abstract::In two different controlled prospective randomized trials the Lung Cancer Study Group has shown that adjuvant CAP chemotherapy is effective in prolonging the disease-free survival. These studies indicate that the adjuvant chemotherapy has its effect by way of diminishing systemic recurrences and that the adjuvant ther...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Holmes EC

    更新日期:1988-06-01 00:00:00

  • New antimetabolites in the treatment of human malignancies.

    abstract::Several new antimetabolites have been evaluated in clinical trials in recent years. Those with the most promising activity include the structurally related purine analogs fludarabine, 2-chlorodeoxyadenosine, and 2'-deoxycoformycin. These compounds have shown impressive activity against a broad spectrum of indolent lym...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Cheson BD

    更新日期:1992-12-01 00:00:00

  • Current strategies for locoregionally advanced unresectable non-small cell lung cancer.

    abstract::Locoregionally advanced unresectable non-small cell lung cancer is defined by bulky primary site disease and/or regionally advanced lymphadenopathy involving the contralateral mediastinum and/or supraclavicular lymph nodes. These tumors are not amenable to curative-intent surgical resection but can be approached with ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Vokes EE,Green MR

    更新日期:1999-10-01 00:00:00

  • The development of busulfan/cyclophosphamide preparative regimens.

    abstract::Bone marrow transplantation (BMT) preparative regimens consisting of busulfan (Bu) and cyclophosphamide (Cy) were developed as an alternative to preparative regimens based on total body irradiation (TBI). Animal studies demonstrated that Bu had a high level of myeloablative and antileukemic activity, but little immuno...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Santos GW

    更新日期:1993-08-01 00:00:00

  • Autoimmune complications of chronic lymphocytic leukemia.

    abstract::Autoimmune complications are common in chronic lymphocytic leukemia (CLL), occurring in up to a quarter of all patients during the course of the illness. By far the most common manifestation is autoimmune hemolytic anemia (AIHA), followed by immune thrombocytopenia (ITP). It is not true to say that autoimmunity is con...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.01.011

    authors: Hamblin TJ

    更新日期:2006-04-01 00:00:00

  • Imaging of lung cancer: old and new.

    abstract::Lung cancer is the leading cause of cancer death in the United States. Lung cancer is frequently encountered by the radiologist, whether the lung cancer is detected on a chest radiograph obtained in a symptomatic patient, or is an incidental finding. The radiologic workup of pulmonary lesions suspected of being lung c...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Broderick LS,Tarver RD,Conces DJ Jr

    更新日期:1997-08-01 00:00:00

  • Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study.

    abstract::This phase I trial was designed to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin (400 mg/m2) as first-line chemotherapy for stage IIIC/IV ovarian adenocarcinoma. After premedication, paclitaxel was infu...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Lhommé C,Kerbrat P,Lejeune C,Guastalla JP,Fumoleau P,Goupil A,Héron JF,Cassin MA,Pruvot I,Soares JA,Chazard M

    更新日期:1996-10-01 00:00:00

  • Metabolic emergencies in the cancer patient.

    abstract::The acute tumor lysis syndrome (ATLS) is characterized by the rapid development of hyperuricemia, hyperkalemia, hyperphosphatemia, and acute renal failure (ARF). Hematologic malignancies are responsible for most cases of ATLS. Control of hyperuricemia and the achievement of a high urine flow are the mainstays of preve...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Flombaum CD

    更新日期:2000-06-01 00:00:00

  • Molecular biology of colorectal cancer: new targets.

    abstract::Colorectal cancer is an ideal model in which to study malignant progression from the molecular-genetic perspective because different stages of the same malignancy coexist within each patient. Approximately 75% of colorectal cancer cases are sporadic and the remaining are familial disease, yet genetic mutations that ha...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.10.003

    authors: Kitisin K,Mishra L

    更新日期:2006-12-01 00:00:00

  • Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.

    abstract::The discovery of the HER2/neu proto-oncogene and its role in the pathogenesis of breast cancer tumors, and the development of the anti-HER2 monoclonal antibody, trastuzumab (Herceptin; Genentech, South San Francisco, CA), directed against the HER2 receptor represent major milestones in the research developments in bre...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90188-5

    authors: Slamon D,Pegram M

    更新日期:2001-02-01 00:00:00

  • Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment.

    abstract::Intra-arterial (IA) therapies for hepatocellular carcinoma (HCC) are considered palliative and should be offered to patients with intermediate-stage multinodular disease and with sufficient liver reserve. They include transarterial chemoembolization (TACE) or bland embolization, transarterial chemotherapy, and transar...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2010.03.007

    authors: Tsochatzis EA,Germani G,Burroughs AK

    更新日期:2010-04-01 00:00:00

  • Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia.

    abstract::Immune dysregulation, a hallmark of chronic lymphocytic leukemia (CLL), manifests itself in three autoimmune diseases: warm autoimmune hemolytic anemia (AIHA); idiopathic thrombocytopenia (ITP); and, pure red cell aplasia (PRCA). AIHA occurs in 11% of advanced stage CLL patients. Prednisone is the first treatment of c...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Diehl LF,Ketchum LH

    更新日期:1998-02-01 00:00:00

  • Recent advances in pathologic evaluation and reporting of melanoma.

    abstract::Recent changes to the staging of melanoma, coupled with advances in surgical and medical treatment, have resulted in new methods for diagnostic evaluation and reporting of melanocytic lesions by pathologists. This review provides an update on recent changes in evaluation and reporting of primary melanoma, evaluation o...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2012.01.005

    authors: Mathew R,Messina JL

    更新日期:2012-04-01 00:00:00

  • Other options in the treatment of advanced breast cancer.

    abstract::Many cytotoxic therapies are available for patients with metastatic breast cancer, but response rates are low and acquired or de novo resistance is virtually universal. Among the agents that are used in the treatment of pretreated metastatic breast cancer are vinorelbine, gemcitabine, nab-paclitaxel, pemetrexed, plati...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2011.04.005

    authors: Cobleigh MA

    更新日期:2011-06-01 00:00:00